Sphingosine 1-Phosphate (S1P) Receptor Modulators as an Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Syed Anjum Ali Gardezi, Muhammad Javaid Iqbal, Sami Ulhaq et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis pooled eight randomized controlled trials involving 2663 adults with ulcerative colitis, comparing sphingosine-1-phosphate receptor modulators with placebo. The treatments improved clinical response, remission, endoscopic and histological outcomes, and mucosal healing during induction and maintenance. The largest reported relative effect was for clinical response during maintenance (RR 3.30; p = 0.0002). Adverse events were slightly more frequent with modulators, while serious adverse events and treatment discontinuations did not differ significantly. The authors describe induction efficacy as consistent across outcomes and maintenance effects as more modest or variable.
Key findings
- Clinical response increased during induction (RR 2.47; p < 0.00001) and maintenance (RR 3.30; p = 0.0002).
- Clinical remission improved during induction (RR 1.84; p < 0.00001) and maintenance (RR 2.20; p = 0.0001).
- Histological remission improved during induction (RR 2.59; p < 0.00001) and maintenance (RR 2.60; p < 0.00001).
- Adverse events were slightly increased (RR 1.13; p = 0.002); serious adverse events and discontinuations did not differ significantly from placebo.
Why it matters
The pooled findings suggest that S1P receptor modulators can improve both clinical and tissue-based outcomes in adults with moderate to severe ulcerative colitis, including during maintenance. Considering efficacy alongside the modest increase in adverse events helps frame their potential role, while the variability of maintenance effects and the absence of significant differences in serious adverse events or discontinuations remain relevant to interpretation.
What to keep in mind
The analysis combines eight trials of several different S1P receptor modulators; the abstract notes that maintenance effects were more modest or variable.